Maintenance ECT in Affective Disorders

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
D. Barrocas ◽  
R. Coentre ◽  
I. Chendo ◽  
T. Mendes ◽  
M. Abreu ◽  
...  
Keyword(s):  
Affective Disorders ◽  
Hospital Admissions ◽  
Bipolar Depression ◽  
Efficacy And Safety ◽  
Therapeutic Tool ◽  
Frequent Relapses ◽  
Maintenance Ect ◽  
Santa Maria ◽  
Term Management

ECT is the most powerful therapeutic tool in the treatment of acute mood episodes. However, data on the efficacy and safety of ECT in the long term management of affective disorders is lacking, despite overwhelming rates of chronicity and/or frequent relapses among patients with unipolar and bipolar depression. In this presentation we will review the data of the ECT unit of Hospital de Santa Maria, Lisboa, on maintenace ECT (m-ECT) in these patients. We compare intra and inter-individual evolution prior and after the institution of m-ECT. Considering the number of hospital admissions, mood symptoms and other parameters, our data support the use of this technique as a prophylatic approach for patients with mood disorders and a previous good response to ECT in the acute phase of disease.

Maintenance ECT in Affective Disorders

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
D. Barrocas ◽  
R. Coentre ◽  
I. Chendo ◽  
T. Mendes ◽  
M. Abreu ◽  
...  
Keyword(s):  
Affective Disorders ◽  
Hospital Admissions ◽  
Bipolar Depression ◽  
Efficacy And Safety ◽  
Therapeutic Tool ◽  
Frequent Relapses ◽  
Maintenance Ect ◽  
Santa Maria ◽  
Term Management

ECT is the most powerful therapeutic tool in the treatment of acute mood episodes. However, data on the efficacy and safety of ECT in the long term management of affective disorders is lacking, despite overwhelming rates of chronicity and/or frequent relapses among patients with unipolar and bipolar depression. In this presentation we will review the data of the ECT unit of Hospital de Santa Maria, Lisboa, on maintenace ECT (m-ECT) in these patients. We compare intra and inter-individual evolution prior and after the institution of m-ECT. Considering the number of hospital admissions, mood symptoms and other parameters, our data support the use of this technique as a prophylatic approach for patients with mood disorders and a previous good response to ECT in the acute phase of disease.

scholarly journals Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies

2019 ◽  
Vol 49 (4) ◽  
pp. 271-280 ◽  
Author(s):  
Tadao Akizawa ◽  
Iain C. Macdougall ◽  
Jeffrey S. Berns ◽  
Thomas Bernhardt ◽  
Gerald Staedtler ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Hypoxia Inducible Factor ◽  
Efficacy And Safety ◽  
Open Label ◽  
Multicenter Studies ◽  
Parallel Group ◽  
The Mean ◽  
Term Management

Background: Molidustat, a novel hypoxia-inducible factor-prolyl hydroxylase inhibitor, is being investigated for the treatment of anemia associated with chronic kidney disease (CKD). The efficacy and safety of molidustat were recently evaluated in three 16-week phase 2b studies. Here, we report the results of two long-term extension studies of molidustat. Methods: Both studies were parallel-group, open-label, multicenter studies of ≤36 months’ duration, in patients with anemia due to CKD, and included an erythropoiesis-stimulating agent as active control. One study enrolled patients not receiving dialysis (n = 164), and the other enrolled patients receiving hemodialysis (n = 88). The primary efficacy variable for both studies was change in blood hemoglobin (Hb) level from baseline to each post-baseline visit, and safety outcomes included adverse events (AEs). Results: In patients not on dialysis, the mean ± SD Hb concentrations at baseline were 11.28 ± 0.55 g/dL for molidustat and 11.08 ± 0.51 g/dL for darbepoetin. The mean ± SD blood Hb concentrations throughout the study (defined as mean of each patient’s overall study Hb levels) were 11.10 ± 0.508 and 10.98 ± 0.571 g/dL in patients treated with molidustat and darbepoetin, respectively. Similar proportions of patients reported at least one AE in the molidustat (85.6%) and darbepoetin (85.7%) groups. In patients on dialysis, mean ± SD Hb levels at baseline were 10.40 ± 0.70 and 10.52 ± 0.53 g/dL in the molidustat and epoetin groups, respectively. The mean ± SD blood Hb concentrations during the study were 10.37 ± 0.56 g/dL in the molidustat group and 10.52 ± 0.47 g/dL in the epoetin group. Proportions of patients who reported at least one AE were 91.2% in the molidustat group and 93.3% in the epoetin group. Conclusions: Molidustat was well tolerated for up to 36 months and appears to be an effective alternative to darbepoetin and epoetin in the long-term management of anemia associated with CKD.

Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism

2018 ◽  
Vol 41 (10) ◽  
pp. 1221-1226 ◽  
Author(s):  
A. Meola ◽  
E. Vignali ◽  
A. Matrone ◽  
F. Cetani ◽  
C. Marcocci
Keyword(s):  
Efficacy And Safety ◽  
Term Management

DBT as a Suicide and Self-harm Treatment

2017 ◽  
pp. 306-324 ◽  
Author(s):  
Lars Mehlum
Keyword(s):  
Hospital Admissions ◽  
Research Literature ◽  
Borderline Personality ◽  
Emergency Room Visits ◽  
Behaviour Therapy ◽  
Associated Symptoms ◽  
Self Harm ◽  
The Many ◽  
Term Management

Dialectical behaviour therapy (DBT) was developed to treat suicidal and self-harming behaviours in patients with Borderline Personality Disorder (BPD), frequently perceived as extremely challenging to treat by many clinicians. This chapter reviews these challenges and demonstrates what strategies DBT adopts both in crisis intervention and long-term management to prevent suicide and non-suicidal self-harm. It, furthermore, reviews the research literature on the treatment outcome and efficacy of DBT to reduce these behaviours, their associated symptoms and consequential emergency room visits and psychiatric hospital admissions. The chapter then discusses which of the many therapeutic strategies DBT uses are likely to be the most important mechanisms of change with respect to reducing self-harming behaviours.

Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children

PEDIATRICS ◽  
2002 ◽  
Vol 110 (1) ◽  
pp. e2-e2 ◽  
Author(s):  
U. Wahn ◽  
J. D. Bos ◽  
M. Goodfield ◽  
R. Caputo ◽  
K. Papp ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Efficacy And Safety ◽  
Term Management

Case Studies in Bipolar Depression: Best Practices for the Outpatient

CNS Spectrums ◽  
2007 ◽  
Vol 12 (S20) ◽  
pp. 4-13
Author(s):  
Paul E. Keck ◽  
Roger S. McIntyre ◽  
Richard C. Shelton
Keyword(s):  
Best Practices ◽  
Bipolar Depression ◽  
Preventive Treatment ◽  
Term Treatment ◽  
Case Examples ◽  
Long Term Treatment ◽  
Bipolar Patients ◽  
Term Management ◽  
Depressive States

Clinicians are fairly comfortable with the management of acute mania because of the abundance of research studies available. However, there are several important aspects of bipolar disorder that the field has been far less successful with, including management of acute and preventive treatment of bipolar depression, comorbid illnesses, and break-through depression in the context of long-term treatment. There is tremendous complexity in the various symptoms and behavioral dimensions associated with bipolar depression. To facilitate understanding of bipolar depression, this article focuses on treating and managing the bipolar outpatient at risk for a depressive relapse. The discussion poses several challenges associated with bipolar depression and addresses the morbidity of depressive states as well as acute and long-term management of this disorder. The best practices for the varying clinical states of bipolar depressive disorder will be demonstrated through two case examples of patients struggling with disturbances common in bipolar patients.

Sign in / Sign up

Export Citation Format

Share Document